PPF34 Dexamethasone and levetiracetam in continuous subcutaneous infusion (CSCI): a case review

Read full text Summarise with VIRAT
Authors: Molly Jakes, Arabella Atkins, Mette B Larsen
Cited by: 0
References: 4

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background The use of dexamethasone and levetiracetam in combination via continuous subcutaneous infusion (CSCI) remains underreported in the literature, with no established guidelines supporting their concurrent administration in a syringe driver.1–3 However, this combination may offer significant clinical benefits for patients with intracranial metastatic disease or primary brain tumours, where both corticosteroids and anticonvulsants are often essential for symptom and seizure control. The lack of compatibility data can result in multiple infusion devices or reliance on painful subcutaneous dexamethasone injections. Case This case describes a patient with glioblastoma and a history of seizures, receiving treatment with dexamethasone and levetiracetam (2.5 g/day). The patient’s oral route became unreliable, therefore both dexamethasone and levetiracetam required subcutaneous delivery. The patient was unable to tolerate s/c dexamethasone due to pain at injection site, so both had to be given via CSCI. Due to volume constraints, the treatment was delivered using two syringe drivers. Initially, the levetiracetam was divided between the drivers (1.5 g and 1 g), with 3.3 mg dexamethasone added to each. Initial mixing gave no precipitate and was infused via CSCI for 6 days without issue. On day 6 the patient developed site reactions and visible fluid collections. Raising concerns about crystallisation. There were no changes in volume infused and the diluent used was water for injection. Upon reducing the dexamethasone dose to 2.5 mg per driver, the complications resolved, suggesting a dose-dependent compatibility threshold longer term. There were no further local complications or need for additional injections, which aligned with the patient‘s preferences. Conclusion This case highlights the potential for co-administering dexamethasone and levetiracetam in CSCI under specific dosing parameters. While further research is needed to establish formal compatibility data and guidelines, cautious dose adjustment may allow for effective, patient-centred management while reducing treatment burden in palliative care settings. References Levetiracetam management [Internet]. [cited 2025 May 9]. Available from: https://www.westmidspallcare.co.uk/specialist-guidelines/spagg-guide/subcutaneous-levetiracetam/levetiracetam-management/ Wilcock A, Howard P, Charlesworth S. PCF7 : palliative care formulary. London: Pharmaceutical Press; 2020.(p 313). Dickman A, Schneider J. The Syringe Driver . 4th Edition. Oxford: Oxford University Press; 2016.(p 130).

Fields of Study & Subjects

Intravenous Infusion Technology and Safety Central Venous Catheters and Hemodialysis Pain Management and Opioid Use

Publication details

Journal / source
BMJ Supportive & Palliative Care
Pages
A56.1–A56
Publication date
25 March 2026
Language
EN